Diabetes Drug Leads Bioactive Peptide Library
$7,872.00
160 bioactive peptides for diabetes drug discovery, GLP-1 pathway research, insulin secretion, and metabolic syndrome. Clinical RX Center.
Diabetes Drug Leads Bioactive Peptide Library (Cat# L-012)
The Diabetes Drug Leads Bioactive Peptide Library is a focused collection of 160 bioactive peptides with established or potential roles in glucose homeostasis, insulin secretion, and metabolic regulation. This library is the premier resource for researchers working on type 2 diabetes, GLP-1 receptor agonism, and metabolic syndrome.
Key Research Applications
- GLP-1 and GIP receptor agonist screening
- Insulin secretagogue identification
- Pancreatic beta-cell function studies
- Glucagon and amylin pathway research
- Anti-diabetic peptide lead optimization
- Metabolic syndrome and obesity comorbidity research
Product Specifications
| Catalog Number | L-012 |
|---|---|
| Library Size | 160 peptides |
| Format | 96-well plate(s) |
| Content per Well | 1.5 nmol peptide in 15 µg BSA |
| Purity | ≥95% by HPLC |
| Storage | Store at 4°C |
| Origin | Made in USA |
| Certification | ISO 9001 | CoA included |
| List Price | $7,872 |
For Research Use Only.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.